TransBarrier® specializes in helping individuals recover from stroke, even if severe, using its innovative, patented TransBarrier® drug delivery method. TransBarrier’s patented treatment is designed to enhance the selective delivery of drugs across the blood-brain barrier. For further specific information regarding types of treatment responses, please click here. Please see the Terms of Use for this website.
Appointments at TransBarrier®
Consultation and treatment are by appointment only. Phone consultations can be scheduled by calling TransBarrier at +1 (561) 353-9707, Monday through Thursday, 9 AM to 5:30 PM, and Friday, 9 AM to 5 PM Eastern Time.
Referrals to TransBarrier®
TransBarrier® welcomes referrals from neurologists, geriatricians, internists, family physicians, other health care providers, or family members of patients with selected neuroinflammatory disorders. Individual treatment recommendations are only made following medical evaluation, including history, physical examination, and review of imaging studies.
TransBarrier® welcomes telephone inquiries from physicians and family members. In particular, TransBarrier® encourages telephone inquiry and discussion with a TransBarrier® medical provider for those patients referred from locations at a geographic distance from Boca Raton, Florida, prior to appointment scheduling. This is recommended especially for those patients who will be flying across country or from overseas for treatment at TransBarrier®, due to the special nature of the services provided at TransBarrier®, and the unique experience which TransBarrier® has performing anti-TNF treatment for neurological disorders.
TransBarrier® Scientific Background
The scientific findings of have been published in multiple, peer-reviewed medical journals, including articles published in the journals BMC Neurology, Clinical Drug Investigation, Clinical Therapeutics, CNS Drugs, Current Alz. Research, Current Medical Research and Opinion, Drug Discovery Today and Expert Review of Neurotherapeutics. There have been citations to TransBarrier® publications by hundreds of academic scientists from around the world, including in Nature Clinical Practice Neurology and F1000 Biology.
TransBarrier® has presented its scientific findings regarding the effects of anti-TNF for neurological disorders at multiple U.S. and international medical and scientific conferences, including the Karolinska Institute in Sweden; the 2008 Drug Repositioning Summit in Boston; the International Conference on AD in Chicago; the 7th Annual Alz. Drug Discovery Conference in New York; the 2008 Best Practices in the Continuum of Care: Advances in AD Management conference at the University of Arkansas Medical Sciences in Little Rock, Arkansas; and, in 2009, the 3rd International Restauracion Neurologica Conference in Havana, Cuba, the World Pharmaceutical Congress in Philadelphia and the 5th Modern Drug Discovery Conference in San Diego. TransBarrier® has performed collaborative research with scientists from Stanford University School of Medicine and additional academic centers.
Copyright 2021 TransBarrier®, all rights reserved